Allergic Conjunctivitis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1, 8 and 1 respectively for Allergic Conjunctivitis.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Conjunctivitis Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Conjunctivitis - Overview 9
Allergic Conjunctivitis - Therapeutics under Development by Companies 10
Allergic Conjunctivitis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Allergic Conjunctivitis - Products under Development by Companies 14
Allergic Conjunctivitis - Companies Involved in Therapeutics Development 15
Accolade Pharmaceuticals, LLC 15
Aldeyra Therapeutics Inc 16
Allergan Plc 17
Clevexel Pharma SA 18
Griffin Discoveries BV 19
NicOx S.A. 20
Ocular Therapeutix, Inc. 21
Ohr Pharmaceutical Inc. 22
Portola Pharmaceuticals, Inc. 23
Re-Pharm Limited 24
Sylentis S.A.U. 25
Xencor, Inc. 26
Allergic Conjunctivitis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ADX-102 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AGN-229666 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
cetirizine hydrochloride - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CVXL-0074 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
dexamethasone acetate SR - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Drugs for Allergic Conjunctivitis - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
GD-134 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
GD-136 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
PRT-2761 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
RP-0217 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
SYL-116011 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
XmAb-7195 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Zafi-2 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Allergic Conjunctivitis - Dormant Projects 59
Allergic Conjunctivitis - Discontinued Products 61
Allergic Conjunctivitis - Product Development Milestones 62
Featured News & Press Releases 62
Sep 26, 2016: Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day 62
Jun 06, 2016: Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis 62
Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis 64
Dec 16, 2015: Aldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis 64
Nov 24, 2015: Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 65
Nov 12, 2015: Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA for Treatment of Allergic Conjunctivitis 65
Oct 22, 2015: Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 66
Sep 29, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial 67
Jun 16, 2015: Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 67
Nov 24, 2014: Ora-CAC Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix's OTX-DP in Allergic Conjunctivitis 68
Nov 12, 2014: Ocular Therapeutix Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Allergic Conjunctivitis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 15
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H2 2016 16
Allergic Conjunctivitis - Pipeline by Allergan Plc, H2 2016 17
Allergic Conjunctivitis - Pipeline by Clevexel Pharma SA, H2 2016 18
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2016 19
Allergic Conjunctivitis - Pipeline by NicOx S.A., H2 2016 20
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H2 2016 21
Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc., H2 2016 22
Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 23
Allergic Conjunctivitis - Pipeline by Re-Pharm Limited, H2 2016 24
Allergic Conjunctivitis - Pipeline by Sylentis S.A.U., H2 2016 25
Allergic Conjunctivitis - Pipeline by Xencor, Inc., H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Allergic Conjunctivitis - Dormant Projects, H2 2016 59
Allergic Conjunctivitis - Dormant Projects (Contd..1), H2 2016 60
Allergic Conjunctivitis - Discontinued Products, H2 2016 61